Hélène Zéphir

9.8k total citations · 1 hit paper
121 papers, 3.4k citations indexed

About

Hélène Zéphir is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Hélène Zéphir has authored 121 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pathology and Forensic Medicine, 64 papers in Neurology and 31 papers in Rheumatology. Recurrent topics in Hélène Zéphir's work include Multiple Sclerosis Research Studies (82 papers), Peripheral Neuropathies and Disorders (48 papers) and Systemic Lupus Erythematosus Research (23 papers). Hélène Zéphir is often cited by papers focused on Multiple Sclerosis Research Studies (82 papers), Peripheral Neuropathies and Disorders (48 papers) and Systemic Lupus Erythematosus Research (23 papers). Hélène Zéphir collaborates with scholars based in France, United States and Canada. Hélène Zéphir's co-authors include J. de Sèze, Patrick Vermersch, Olivier Outteryck, Frédéric Blanc, Romain Marignier, Sandra Vukusic, Christine Lebrun‐Frénay, Nicolas Collongues, Henry A. Homburger and Vanda A. Lennon and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Brain.

In The Last Decade

Hélène Zéphir

112 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuromyelitis Optica and Non–Organ-Specific Autoimmunity

2008 448 citations J. de Sèze, Patrick Vermersch et al. profile →

Peers

Countries citing papers authored by Hélène Zéphir

Since Specialization

Citations

This map shows the geographic impact of Hélène Zéphir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène Zéphir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène Zéphir more than expected).

Fields of papers citing papers by Hélène Zéphir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène Zéphir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène Zéphir. The network helps show where Hélène Zéphir may publish in the future.

Co-authorship network of co-authors of Hélène Zéphir

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène Zéphir. A scholar is included among the top collaborators of Hélène Zéphir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène Zéphir. Hélène Zéphir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis 2025 ·Neurotherapeutics ·(unknown), (unknown), (unknown), Jan‐Patrick Stellmann, (unknown), (unknown), (unknown), (unknown), (unknown), Clémence Boutière, Audrey Rico, (unknown), (unknown), Jean Pelletier, (unknown), Hélène Zéphir, Bertrand Audoin	2
2	Life-threatening immune-related adverse events in the intensive care unit: a narrative review 2025 ·Intensive Care Medicine ·(unknown), (unknown), Côme Bureau, (unknown), (unknown), (unknown), Pauline Wils, E. Merlen, Arnaud Lionet, Louis Terriou, (unknown), (unknown), Hélène Zéphir, Massih Ningarhari, Vincent Sobanski, Arnaud Scherpereel, Alexandra Forestier, David Launay, (unknown)	0
3	Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome 2024 ·Multiple Sclerosis Journal ·(unknown), Vito A. G. Ricigliano, Lydiane Mondot, Éric Thouvenot, Pierre Labauge, Céline Louapre, Hélène Zéphir, (unknown), Emmanuelle Le Page, Aksel Sıva, Mikaël Cohen, (unknown), Christina Azevedo, Darin T. Okuda, Bruno Stankoff, Christine Lebrun‐Frénay	5
4	Fiches pratiques thérapeutiques pour la prise en charge des patients atteints de sclérose en plaques 2023 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Hélène Zéphir, (unknown), Emmanuelle Le Page	0
5	Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: Are we missing something? 2023 ·Revue Neurologique ·(unknown), Laurent Mortier, Julien Lannoy, Sylvain Dubucquoi, Hélène Zéphir	1
6	Training first-year medical residents to break bad news using healthcare role-play and trainees as simulated patients: Experience of the “ADIAMED” program from Lille University School of Medicine 2023 ·La Revue de Médecine Interne ·(unknown), Sébastien Sanges, P. Guerreschi, É. Wiel, Gilles Lebuffe, (unknown), M. Jourdain, S. Morell‐Dubois, Hélène Zéphir	0
7	Evaluation of risk management in a natalizumab home infusion procedure 2023 ·Revue Neurologique ·(unknown), (unknown), Jonathan Giovannelli, Jérôme Petit, Olivier Outteryck, (unknown), Hélène Zéphir	2
8	Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy 2023 ·Neurotherapeutics ·(unknown), (unknown), (unknown), (unknown), Olivier Outteryck, Myriam Labalette, (unknown), Sylvain Dubucquoi, Hélène Zéphir	7
9	Time to steroids impacts visual outcome of optic neuritis in MOGAD 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Julie Pique, Adil Maarouf, Xavier Ayrignac, Bertrand Bourre, Jonathan Ciron, Mikaël Cohen, Nicolas Collongues, Romain Deschamps, Élisabeth Maillart, Alexis Montcuquet, Caroline Papeix, Aurélie Ruet, Sandrine Wiertlewski, Hélène Zéphir, Romain Marignier, Bertrand Audoin	18
10	A Spontaneous Model of Experimental Autoimmune Encephalomyelitis Provides Evidence of MOG-Specific B Cell Recruitment and Clonal Expansion 2022 ·Frontiers in Immunology ·(unknown), (unknown), Frédéric Leprêtre, Martin Figeac, Thomas Guerrier, (unknown), (unknown), (unknown), Anneli Peters, Lennart T. Mars, Hélène Zéphir	10
11	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP) 2021 ·Multiple Sclerosis and Related Disorders ·Kévin Bigaut, Mikaël Cohen, Françoise Durand‐Dubief, Élisabeth Maillart, (unknown), Hélène Zéphir, Christine Lebrun‐Frénay, J. de Sèze	16
12	Asymptomatic optic nerve lesions 2020 ·Neurology ·Jean‐Baptiste Davion, Renaud Lopes, Élodie Drumez, Julien Labreuche, (unknown), Julien Lannoy, Patrick Vermersch, Jean‐Pierre Pruvo, X. Leclerc, Hélène Zéphir, Olivier Outteryck	36
13	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort 2020 ·Multiple Sclerosis Journal ·Kévin Bigaut, Thibaut Fabacher, Laurent Kremer, (unknown), Arnaud Kwiatkowski, François Sellal, D. Ferriby, Sylvie Courtois, Patrick Vermersch, Nicolas Collongues, Hélène Zéphir, J. de Sèze, Olivier Outteryck	11
14	Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome 2020 ·Neurology ·Olivier Outteryck, Renaud Lopes, Élodie Drumez, Julien Labreuche, Julien Lannoy, (unknown), (unknown), Patrick Vermersch, (unknown), Jean‐Pierre Pruvo, Hélène Zéphir, X. Leclerc	20
15	Multiple sclerosis and pregnancy 2014 ·Revue Neurologique ·Eric Bodiguel, Caroline Bensa, David Brassat, David Laplaud, Emmanuelle Le Page, Jean‐Christophe Ouallet, Hélène Zéphir, J. de Sèze	15
16	Aquaporin-4 antibody–negative neuromyelitis optica 2013 ·Neurology ·Romain Marignier, Raphaël Bernard‐Valnet, Pascale Giraudon, Nicolas Collongues, Caroline Papeix, Hélène Zéphir, Gaëlle Cavillon, Véronique Rogemond, Romain Casey, Bernard Frangoulis, J. de Sèze, Sandra Vukusic, Jérôme Honnorat, Christian Confavreux, (unknown)	127
17	Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study 2012 ·BMC Neurology ·Patrick Vermersch, (unknown), Nicolás Schmidt, Hélène Zéphir, Pierre Clavelou, (unknown), Patrice Dubreuil, Alain Moussy, Olivier Hermine	95
18	Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica 2010 ·European Journal of Neurology ·Jean‐Baptiste Chanson, Hélène Zéphir, Nicolas Collongues, Olivier Outteryck, Frédéric Blanc, Marie Fleury, Patrick Vermersch, J. de Sèze	50
19	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion 2009 ·Multiple Sclerosis Journal ·Gauthier Calais, G Forzy, (unknown), (unknown), J. de Sèze, Frédéric Blanc, Christine Lebrun‐Frénay, Olivier Heinzlef, Pierre Clavelou, Thibault Moreau, Bernadette Hennache, Hélène Zéphir, (unknown), (unknown), Christian Confavreux, Patrick Vermersch, Patrick Hautecœur	42
20	[Epstein-Barr meningoencephaloradiculitis in a immunocompetent woman]. 2002 ·PubMed ·Hélène Zéphir, J. de Sèze, D. Ferriby, T. Stojkovic, P. Vermersch	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact